Impact of prognostic factors on long-term outcomes in metastatic breast cancer (MBC) patients (pts) receiving bevacizumab (B) plus paclitaxel as first-line cytotoxic treatment.

e12007 Background: B combined with chemotherapy (CT) significantly improves progression-free survival (PFS) and response rate (RR) vs CT alone in the first-line treatment of HER2-negative MBC. In a large German prospective, non-interventional study, we examined the impact of standard prognostic factors in a population of pts homogeneously treated with an antibody/taxane combination. Methods: Pts who had received no prior CT for their MBC received B+paclitaxel per the European label. Efficacy and safety were documented in detail for up to 1 year (or until progression, death, or B discontinuation, if earlier), with subsequent retrieval of long-term follow-up. Results: By April 2013, final data were available for 865 pts, with PFS events recorded in 715 pts (83%) and OS events in 524 pts (61%). The prognostic effect of various baseline characteristics is presented in the table. Overall best response (CR+PR) does generally show no major association to the factors analyzed, except for a lower efficacy in tripl...